Before joining Moderna, Cronin spent close to 20 years at Ogilvy, working within its global healthcare department in ...

At the ongoing TD Cowen Health Care conference on Wednesday, Moderna (NASDAQ:MRNA) President Stephen Hoge noted that a late-stage trial designed to test the company's cancer shot V940 against skin ...

We're on day three here. Excited to kick things off with the company sessions with a fireside chat of Moderna. It's my pleasure to introduce Stephen Hoge, the President of -- Hodge? Sure.

Moderna's President Stephen Hoge stated, “As you know, and as I mentioned, there are additional Phase 3s as well as two randomized Phase 2s, including bladder cancer and renal cell carcinoma ...

The primary endpoint is recurrence-free survival at 12 months, with first results expected late this quarter, according to Moderna's president, Stephen Hoge. "We continue to be excited about the ...

Moderna CEO Stéphane Bancel received $19.9 million in total ... 2023 and well exceeding the $11.4 million she brought home in 2021. Meanwhile, president Stephen Hoge, MD received $9.1 million last ...

Moderna is currently in a late-stage trial for a vaccine for skin cancer. Speaking at an investor conference on Wednesday, President Stephen Hoge said the company’s cancer vaccine could be a “quite ...

This page features the latest news about the Moderna DRC share. Moderna president Hoge sells $21,362 in company stock In recent trading activity, Stephen Hoge, the President of Moderna , Inc.